Takeru Shiroiwa

Chief Senior Researcher

National Institute of Public Health

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Takeru Shiroiwa is a Chief Senior Researcher at the National Institute of Public Health (NIPH) in Japan. His research areas include health technology assessment, preference-based measures, and cost-effectiveness analysis, with recent articles focusing on health-related quality of life and valuation surveys. He has contributed to the development of culturally specific measures in East and Southeast Asia and has examined the reliability of web-based surveys compared to traditional methods.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (2)

John Brazier

University of Sheffield

UNITED KINGDOM

View details

Donna Rowen

Professor of Health Economics

University of Sheffield

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Takeru Shiroiwa

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Convergent validity, reliability and responsiveness of the AP-7D and EQ-5D-5L based on the survey for the general people in five countries: a new cultural-specific preference-based measure developed in east and southeast asia

Valuation survey for SF-6Dv2 in Japan based on the international protocol

Japanese value set for the EORTC QLU-C10D: A multi-attribute utility instrument based on the EORTC QLQ-C30 cancer-specific quality-of-life questionnaire

Are Web-Based Valuation Surveys for Preference-Based Measures as Reliable as Face-to-Face Surveys? TTO, DCE and DCE with Duration

Comparison of four value sets derived using different TTO and DCE approaches: application to the new region-specific PBM, AP-7D

Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches

Japanese preference weights of the Adult Social Care Outcomes Toolkit for Carers (ASCOT-Carer)

Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.

Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study.

Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.

Collaborators (2)

John Brazier

Donna Rowen

Make your next move.